Members of management of Surgery Partners will be meeting with investors today, January 8, 2024, as part of the 42nd Annual J.P. Morgan Healthcare Conference, including a presentation at 5:15 p.m. ET. Based on results through November 2023, the Company is re-affirming its 2023 Adjusted EBITDA guidance of $436 million to $440 million and its 2023 Revenue guidance of approximately $2.75 billion. Additionally, consistent with managements commitment to driving mid-teens growth, the Company projects 2024 Adjusted EBITDA to be greater than $495 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SGRY:
- Surgery Partners, Inc. to Present at Upcoming Investor Conference
- Surgery Partners 8M share Spot Secondary priced at $33.75
- Surgery Partners, Inc. Announces Proposed Secondary Offering of Common Stock
- Surgery Partners announces 8M share common stock offering for holders
- Surgery Partners price target lowered by $4 at JPMorgan, here’s why
